Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial

H. Pott-Junior; G. Bricks; G. Grandi; J. Figueiredo Senise; A. Castelo Filho

doi:10.1016/j.cmi.2018.06.007

Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial

Clinical Microbiology and Infection ◽

10.1016/j.cmi.2018.06.007 ◽

2019 ◽

Vol 25 (3) ◽

pp. 365-371 ◽

Cited By ~ 4

Author(s):

H. Pott-Junior ◽

G. Bricks ◽

G. Grandi ◽

J. Figueiredo Senise ◽

A. Castelo Filho

Keyword(s):

Clinical Trial ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Randomized Clinical Trial ◽

Genotype 1 ◽

Virus Genotype

Download Full-text

Head-to-head clinical Trial of Sofosbuvir plus Daclatasvir or Simeprevir for 12 weeks in Non-cirrhotic subjects with significant fibrosis infected with chronic Hepatitis C Virus genoType 1 (TNT-1 Study)

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2018.04.4264 ◽

2018 ◽

Vol 73 ◽

pp. 376

Author(s):

H. Pott Junior ◽

G. Bricks ◽

G. Grandi ◽

J. Senise ◽

A. Castelo

Keyword(s):

Clinical Trial ◽

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Significant Fibrosis ◽

Chronic Hepatitis C Virus

Download Full-text

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2008.03628.x ◽

2008 ◽

Vol 27 (9) ◽

pp. 810-819 ◽

Cited By ~ 5

Author(s):

K. H. TANG ◽

E. HERRMANN ◽

I. PACHIADAKIS ◽

E. PAULON ◽

N. TATMAN ◽

...

Keyword(s):

Clinical Trial ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Duration ◽

Individualized Treatment ◽

Genotype 1 ◽

Virus Genotype

Download Full-text

Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon α-2a in hepatitis C virus genotype 1 true non-responder patients

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2007.03470.x ◽

2007 ◽

Vol 26 (8) ◽

pp. 1131-1138 ◽

Cited By ~ 23

Author(s):

M. DIAGO ◽

J. CRESPO ◽

A. OLVEIRA ◽

R. PÉREZ ◽

R. BÁRCENA ◽

...

Keyword(s):

Clinical Trial ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Fixed Dose ◽

Genotype 1 ◽

Virus Genotype ◽

Peginterferon Α

Download Full-text

IL28B genetic variation and ratio of y-GT/ALT as predictors for virological response in chronic hepatitis C virus genotype 1 infected patients

Zeitschrift für Gastroenterologie ◽

10.1055/s-0031-1295892 ◽

2012 ◽

Vol 50 (01) ◽

Author(s):

A Amanzada ◽

S Schneider ◽

F Moriconi ◽

M Blaschke ◽

T Suermann ◽

...

Keyword(s):

Genetic Variation ◽

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Virological Response ◽

Genotype 1 ◽

Virus Genotype ◽

Chronic Hepatitis C Virus

Download Full-text

Faculty Opinions recommendation of The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717967213.793466971 ◽

2012 ◽

Author(s):

Reto Nüesch

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Relative Efficacy ◽

Genotype 1 ◽

Virus Genotype

Download Full-text

Faculty of 1000 evaluation for Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020710.793480337 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

Pegylated Interferon Alfa

Download Full-text

Faculty Opinions recommendation of Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718061915.793484659 ◽

2013 ◽

Author(s):

Cihan Yurdaydin

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Randomized Trial ◽

Dose Reduction ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Chronic Hepatitis C Virus

Download Full-text

Faculty Opinions recommendation of Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718087883.793484663 ◽

2013 ◽

Author(s):

Cihan Yurdaydin

Keyword(s):

Clinical Trial ◽

Hepatitis C ◽

Randomized Clinical Trial ◽

Genotype 1 ◽

Treatment Characteristics

Download Full-text

Faculty Opinions recommendation of Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718196356.793490906 ◽

2014 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Randomized Trial ◽

Low Dose ◽

Pegylated Interferon ◽

Genotype 1 ◽

Virus Genotype ◽

Interferon Α2a ◽

Treatment Naïve

Download Full-text

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

Hepatology ◽

10.1002/hep.28467 ◽

2016 ◽

Vol 64 (2) ◽

pp. 370-380 ◽

Cited By ~ 134

Author(s):

Paul Kwo ◽

Norman Gitlin ◽

Ronald Nahass ◽

David Bernstein ◽

Kyle Etzkorn ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Randomized Study ◽

Genotype 1 ◽

Virus Genotype ◽

Phase 3

Download Full-text